Key result
Decellularized aortic homografts for aortic valve replacement demonstrated excellent hemodynamics (mean peak gradient 11.8 mmHg) and 98.4% freedom from explantation at 2.5 years.
Why the study?
Decellularized aortic homografts may offer an additional aortic valve replacement option for young patients by potentially overcoming the high early failure rate of conventional allogenic and xenogenic prostheses.
Are non-cryopreserved decellularized aortic homografts safe and effective for aortic valve replacement in young patients?
Comparison
Non-cryopreserved decellularized aortic homografts
Design
Prospective single-arm multicentre safety study
Follow-up
Mean 1.54 ± 0.81 years
Authors
Loading...
May support DAH as safe AVR option in young patients; leaves open durability versus alternatives in randomized trials.
Cohort (n=144)
Yes
Are non-cryopreserved decellularized aortic homografts safe and effective for aortic valve replacement in young patients?
Decellularized aortic homografts appear safe and provide excellent early hemodynamics for aortic valve replacement in young patients.
Horke et al. (2020) conducted a cohort in Aortic valve replacement (n=144). Decellularized aortic homografts (DAH) vs. Age-matched Ross operation cohort was evaluated on Peak gradient and regurgitation. Decellularized aortic homografts for aortic valve replacement demonstrated excellent hemodynamics (mean peak gradient 11.8 mmHg) and 98.4% freedom from explantation at 2.5 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: